Shopping Cart
- Remove All
- Your shopping cart is currently empty
CHMFL-ABL-053 (Compound 18a) is a potent, selective, and orally available inhibitor of BCR-ABL, SRC, and p38 kinases, with IC50 values of 70, 90, and 62 nM against ABL1, SRC, and p38, respectively. CHMFL-ABL-053 is a potentially useful drug candidate for Chronic Myeloid Leukemia (CML) [1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | 1.444 € | 6-8 weeks | |
50 mg | 1.881 € | 6-8 weeks | |
100 mg | 2.375 € | 6-8 weeks |
Description | CHMFL-ABL-053 (Compound 18a) is a potent, selective, and orally available inhibitor of BCR-ABL, SRC, and p38 kinases, with IC50 values of 70, 90, and 62 nM against ABL1, SRC, and p38, respectively. CHMFL-ABL-053 is a potentially useful drug candidate for Chronic Myeloid Leukemia (CML) [1]. |
In vitro | CHMFL-ABL-053 (Compound 18a) inhibited the proliferation of CML cell lines K562 (GI50 = 14 nM), KU812 (GI50 = 25 nM), and MEG-01 (GI50 = 16 nM). |
In vivo | A 50 mg/kg/day dosage treatment of CHMFL-ABL-053 (Compound 18a) could almost completely suppress tumor progression in the K562 cells inoculated xenograft mouse model. |
Molecular Weight | 549.55 |
Formula | C28H26F3N7O2 |
Cas No. | 1808287-83-3 |
Relative Density. | 1.418 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.